Litigation Details for ARBUTUS PHARMA CORP. v. PFIZER INC. (D.N.J. 2023)

ARBUTUS PHARMA CORP. v. PFIZER INC. (D.N.J. 2023)

Docket		Date Filed	2023-04-04
Court	District Court, D. New Jersey	Date Terminated
Cause	28:1338 Patent Infringement	Assigned To	Zahid Nisar Quraishi
Jury Demand	Both	Referred To	Tonianne J. Bongiovanni
Patents	8,058,069; 8,492,359; 8,822,668; 9,364,435
Link to Docket	External link to docket

Details for ARBUTUS PHARMA CORP. v. PFIZER INC. (D.N.J. 2023)

Date Filed	Document No.	Description	Snippet	Link To Document
2023-04-04	1	Complaint	November 29, 2016 (the “’651 Patent”). b. U.S. Patent No. 8,492,359, “Lipid Formulations for…infringement of the ’651 Patent. COUNT 2: INFRINGEMENT OF U.S. PATENT NO. 8,492,359 80. … acid-based medicines: U.S. Patent Nos. 9,504,651 (Exhibit A); 8,492,359 (Exhibit B); 11,141,378 (Exhibit… them. Among those patents are the Asserted Patents: a. U.S. Patent No. 9,504,651, “Lipid…’320 Patent under 35 U.S.C. § 271(a) by using the patented apparatus covered by the ’320 Patent to make	External link to document
2024-07-11	101	Redacted Document	15, 2008 provisional application: U.S. Patent Nos.: 8,058,069, 8,822,668, and 9,364,435. Case 3:23-cv…success of Comirnaty®, asserting five patents (across two patent families that date back to 2002 and …Comirnaty® infringes those asserted patents. The asserted patents, however, do not claim the specific …attempt by Plaintiffs to leverage the patents-in-suit (or patent family members thereof) into an unearned… of the same patents-in-suit, as well as three additional family members to the patents-in-suit.2 Each	External link to document
2024-07-11	102	Redacted Document	a single excerpt of a claim from U.S. Patent No. 8,492,359 asserted in this case, both excerpts referring…Plaintiffs emphasize each patent’s generic reference to mRNA, and each patent claim’s recitation of “an…Alnylam) is asserting its own patents that are unrelated to the patents in this case. Plaintiffs’ request…this case patents purporting to relate to the discovery of a new lipid ingredient. The patents at issue…claim from just one of the six patents asserted in Alnylam (U.S. Patent 11,382,979), comparing it to a	External link to document
2023-07-10	17	Answer to Complaint	vaccine may infringe Arbutus patents, including at least U.S. Patent Nos. 8,058,069, 8,492,359, 8,822,668… Application issued as U.S. Pat. No. 8,058,069 (the “’069 Patent”) on November 15, 2011. …Office issued the ’651 Patent, ’359 Patent, ’378 Patent, ’320 Patent, and ’098 Patent, but deny that the …“’708 Patent”), 8,329,070 (the “’070 Patent”), and 9,492,386 (the “’386 Patent”). Each patent claims…manufacturing them. Among those patents are the Asserted Patents: a. U.S. Patent No. 9,504,651, “Lipid	External link to document
2023-08-14	29	Answer to Counterclaim	vaccine may infringe Arbutus patents, including at least U.S. Patent Nos. 8,058,069, 8,492,359, 8,822,668, … Application issued as U.S. Pat. No. 8,058,069 (the “’069 Patent”) on November 15, 2011. ANSWER…the Asserted Patents, and unenforceability of the ’378 Patent, ’320 Patent, and ’098 Patent. Plaintiffs…was issued the ’359 Patent, the ’668 Patent, and the ’435 Patent. Those patents speak for themselves… “’708 Patent”), 8,329,070 (the “’070 Patent”), and 9,492,386 (the “’386 Patent”). Each patent claims	External link to document
2024-07-11	99	Redacted Document	of U.S. Patent No. 8,492,359, one of the patents asserted here. For example, the ’979 patent claims, …of U.S. Patent No. 11,382,979, among others. Ex. G at 8-9, 15-18. And the claims of that patent overlap…documents that Pfizer or BioNTech produced in another patent infringement case involving Pfizer’s COVID-19 vaccine…irrelevant because Alnylam “involves different patents.” Ex. B at 6. That is mistaken for multiple independent… 35-65 mol % of a cationic lipid,” and the ’359 patent claims “[a] nucleic acid-lipid particle comprising	External link to document